1. Introduction {#sec0005}
===============

Bovine respiratory disease (BRD) is associated with infectious agents and often complicated by stress factors including environmental, nutrition, transportation, and commingling with cattle of mixed origins and multiple herd sources [@bib0005], [@bib0010]. Infectious agents considered in the etiologies of BRD include viruses: bovine herpesvirus-1 (BHV-1), parainfluenza-3 virus (PI-3V), bovine respiratory syncytial virus (BRSV), bovine viral diarrhea virus (BVDV), bovine adenoviruses (BAV), and bovine coronaviruses (BoCV) and bacteria, *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and Mycoplasma spp. [@bib0005], [@bib0010]. For many years, BHV-1, PI-3V, BRSV, and BVDV were the viruses most associated with the viral etiology of BRD. In contrast, BoCV was associated with neonatal enteric disease and winter dysentery of adult cattle [@bib0015], [@bib0020], [@bib0025]. Recently BoCV as a respiratory infection and disease has received attention and has been the subject of multiple reviews [@bib0030], [@bib0035].

BoCV are enveloped, nonsegmented, positive sense single stranded RNA viruses that are grouped as a species within the *Coronavirus* genus of the *Coronaviridae* family [@bib0040]. BoCV virions contain a large surface glycoprotein referred to as the spike or S protein, an integral membrane protein (M), a small membrane protein (E), a hemagglutinin-esterase glycoprotein (HE) and a nucleocapsid protein (N). While strong humoral responses are elicited against the S, M, N and HE proteins following natural infection, the predominant antigens involved in virus neutralization are located in the S and HE proteins. Various studies have segregated the *Coronavirus* genus into groups based on several criteria, including; position and variation of non-structural proteins in the 3′ end of the genome, antigenic cross reactivity, processing of the S protein and host range. However, there are no set guidelines for defining new *Coronavirus* species or differentiating subgroups within existing species. As stated above BoCV were initially associated with outbreaks of enteric disease. More recently, BoCV have been associated with bovine respiratory disease (BRD) and in cattle pulled for treatment in the feedlot as well as from healthy cattle in numerous studies in the U.S. In these studies BoCV was identified by virus isolation from nasal swabs and bronchoalveolar lavage (BAL) and serotests detecting seroconversions indicating exposure to BoCV in outbreaks of BRD and inapparent infections [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085], [@bib0090], [@bib0095]. BoCV have been identified in pneumonic lungs from field cases, often in combination with other viruses and bacteria including Mycoplasma spp. [@bib0100], [@bib0105], [@bib0110]. Experimentally BoCV have caused respiratory tract lesions affecting the epithelium of the turbinates, trachea, and lungs [@bib0115]. Based on the observation of two different presentations following BoCV exposure, it has been suggested there is a dual tropism by BoCV for respiratory and digestive tracts of cattle [@bib0115], [@bib0120].

Control measures for BoCV respiratory disease are limited. The vaccines available for BoCV are licensed to control of the neonatal enteric disease [@bib0035], [@bib0045], [@bib0125]. There are three inactivated vaccines licensed to control of neonatal enteric disease and these are used in pregnant cows/heifers during pregnancy to stimulate humoral immunity for passive immunization of the newborn calf [@bib0035], [@bib0125]. There is a modified live virus vaccine containing BoCV for administration orally to the newborn calf to provide an active immune response to protect the calf against enteric disease [@bib0035], [@bib0125]. There are no licensed BoCV vaccines in the U.S. to protect against BRD, nor have effectiveness of the licensed enteric BoCV vaccines been determined for protection against BRD with BoCV challenge. However there is one U.S. report using the MLV vaccine containing BoCV that reduced treatment for BRD [@bib0130]. The methods of protection as correlates of immunity were not determined however [@bib0045]. To provide optimal immunity, vaccine antigens should be as similar as possible to the circulating viruses. It appears important that the virus or viruses used as immunogens to control BoCV BRD should align antigenically and genetically with the BoCV circulating in the field.

The purpose of this study was to compare BoCV isolates from the respiratory tract in Oklahoma cattle to reference respiratory and enteric strains and enteric vaccine strains by antigenic and genetic procedures. A valid question being asked, "Are there differences between enteric and respiratory strains isolated as BoCV, and if so, what strain or strains should be used to replace or add to existing BCV enteric vaccines".

2. Materials and methods {#sec0010}
========================

2.1. Source of samples {#sec0015}
----------------------

A total of 56 field strains of BoCV were characterized. Included were samples from cattle not manifesting BRD signs at collection (healthy) and from cattle with BRD signs (BRD). There were multiple sources and studies from which the BoCV strains were derived ([Table 1](#tbl0005){ref-type="table"} ). There were five studies performed at the Oklahoma State University (OSU) Willard Sparks Beef Research Center (WSBRC) feedlot at the Department of Animal Sciences, including four in 2009 (OSU-1,OSU-2,OSU-3, OSU-4) and a fifth in 2011 (OSU-5). All cattle were test negative for BVDV by ear notch immunohistochemistry using skin samples. These calves were auction market purchased calves that were commingled at the auctions and transported to the OSU WSBRC where they were processed receiving identification and MLV vaccines containing BHV-1, PI-3V, BVDV1a, BVDV2a, and BRSV immunogens. Nasal swabs and in some cases bronchoalveolar lavage (BAL) fluids were collected at processing. Sample collections were repeated at weekly times up to 14 days. [@bib0095]. The cattle were placed in pens and a representative [@bib0105], [@bib0110], [@bib0115], [@bib0120], [@bib0125], [@bib0130] group for each study monitored as sentinels. Cattle that were treated for BRD were sampled as well as the sentinel calves. Blood was collected at processing for serums as well as convalescent sera at ≥56 days after arrival. There were in some instances multiple positive BCV samples from the same animal, either from NS and BAL or from sequential collections. In addition NS collected during an OSU study (OSU-6) for a viral challenge study unrelated to BoCV were included in this study. Similarly, nasal swab samples collected from southeastern U.S. sourced cattle that were commingled and delivered to a research facility and monitored for BRD from studies in 1999 (OSU-7) and 2000 (OSU-8) were included. All studies were approved by the OSU Institutional Animal Care and Use Committee (\#VM0818 and \#VM0819).Table 1Identification of Oklahoma bovine coronaviruses from the respiratory tract of cattle.IdentificationHealth statusStudyBoCV cladeOK 554 BALBRDOSU-1BoCV 2cOK 538 BALHealthyOSU-1BoCV 2cOK 542 BALHealthyOSU-1BoCV 2cOK 563 BALHealthyOSU-1BoCV 2c (6)OK 575 NSBRDOSU-1BoCV 2c (6)OK 603 NSBRDOSU-1BoCV 2c (6)OK 521 BAL (17)BRDOSU-1BoCV 2c (6)OK 552 BALHealthyOSU-1BoCV 2c (6)OK 591 BALBRDOSU-1BoCV 2c (6)OK 513 BALHealthyOSU-1BoCV 2c (6)OK 609 BALHealthyOSU-1BoCV 2c (6)OK 521 NSBRDOSU-1BoCV 2c (6)OK 575 BAL (15)BRDOSU-1BoCV 2c (6)OK 545 BALHealthyOSU-1BoCV 2c (6)OK 600 BALBRDOSU-1BoCV 2c (6)OK 603 BALBRDOSU-1BoCV 2c (6)OK 576 BALHealthyOSU-1BoCV 2c (6)OK 592 BALHealthyOSU-1BoCV 2c (6)OK 746 NSHealthyOSU-2BoCV 2b (3)OK 833 NSHealthyOSU-2BoCV 2b (3)OK 746 BALHealthyOSU-2BoCV 2b (3)OK 747 NSHealthyOSU-2BoCV 2b (3)OK 821 NSHealthyOSU-2BoCV 2b (1)OK 801 NSHealthyOSU-2BoCV 2b (1)OK 747 BALHealthyOSU-2BoCV 2b (3)OK 778 NSHealthyOSU-2BoCV 2b (4)OK 778 BALHealthyOSU-2BoCV 2b (4)OK 787 NSBRDOSU-2BoCV 2b (2)OK 802 NS (42)BRDOSU-2BoCV 2b (2)OK 797 NSBRDOSU-2BoCV 2b (2)OK 802 NS (53)BRDOSU-2BoCV 2b (2)OK 766 NSHealthyOSU-2BoCV 2bOK 665 NSHealthyOSU-2BoCV 2bOK 834 NSHealthyOSU-2BoCV 2cOK 3167 NSHealthyOSU-3BoCV 2bOK 3172 NSHealthyOSU-3BoCV 2b (1)OK 3162 NSHealthyOSU-3BoCV 2b (1)OK 3169 NSHealthyOSU-3BoCV 2b (1)OK 3165 NSHealthyOSU-3BoCV 2b (1)OK 3163 NSHealthyOSU-3BoCV 2b (1)OK 3181 NSHealthyOSU-3BoCV 2b (1)OK 3174 NSHealthyOSU-3BoCV 2b (1)OK 3168 NSHealthyOSU-3BoCV 2b (1)OK 3170 NSHealthyOSU-3BoCV 2b (1)OK 3175 NSHealthyOSU-3BoCV 2bOK 3171 NSHealthyOSU-3BoCV 2bOK 3166 NSHealthyOSU-3BoCV 2bOK 1817 NSHealthyOSU-4BoCV 2b (1)OK 1776 NSHealthyOSU-4BoCV 2bOK 776 NSBRDOSU-5BoCV 2cOK 717 NSBRDOSU-5BoCV 2bOK 43 NSHealthyOSU-6BoCV 2b (5)OK 45 NSHealthyOSU-6BoCV 2b (5)OK AN 3 NSHealthyOSU-7BoCV 2aOK AN 5 NSHealthyOSU-7BoCV 2aOK TN 10 NSHealthyOSU-8BoCV 2aBCV NVSLReference strain USDABoCV 1[^1]

2.2. Virus isolation {#sec0020}
--------------------

The BoCV in this study were isolated in human rectal tumor (HRT) monolayer cultures from filtered nasal swabs and/or BAL as described [@bib0095].

2.3. Viral serology {#sec0025}
-------------------

A microtitration virus neutralization test (VNT) was performed in 96-well plates using the HRT cells to quantitate antibodies to BoCV using duplicate rows for the serum dilutions [@bib0095]. Initially the challenge virus was a cytopathic BoCV (USDA APHIS NVSL, Ames, IA), the BoCV NVSL strain. The endpoint was the lowest final/virus tested (1:4) which completely neutralized the viral CPE. The titers were expressed as the reciprocal of the endpoint dilution. Positive and negative controls were utilized. During the study other BoCV were used in the VNT for the serotest comparing different OSU strains isolated from the respiratory tract ([Table 1](#tbl0005){ref-type="table"}). A monoclonal antibody, lot WR99316 BC 28 HI.2C against N protein served as the positive control [@bib0045], [@bib0095].

2.4. Antigenic studies {#sec0030}
----------------------

The antibody titers to several OSU strains in addition to the BoCV NVSL reference strain were compared to determine if the calves' serums were able to neutralize the viral CPE for the respective virus. There were three sera from calves from which BoCV2b was isolated, two sera from calves from which BoCV2c was isolated and three sera from animals from which BoCV2a was isolated. Viruses used in the NVT as challenge virus included five BoCV2b, two BoCV2c, three BoCV2a, and one BoCV1 strain. In [Fig. 2](#fig0010){ref-type="fig"}, the error bars represent standard error of mean. A reference antibody, described above, was used in the study in the VNT with each respective OSU virus. Serums were convalescent compared to determine if the calves' sera were able to neutralize the viral CPE for the respective virus.

2.5. Genetic sequencing {#sec0035}
-----------------------

The BoCV respiratory viruses from the OSU studies along with reference strains and MLV vaccine strain were examined for genomic diversity based on comparison of a region of the S gene. In brief, RNA from the BoCV viruses from the OSU studies along with reference enteric and respiratory and MLV vaccine strains was prepared using the Qiagen Viral RNA mini kit for Qiacube per the manufacturers instructions (Qiagen Inc. USA, Valencia, CA). A 10 μl aliquot of the extracted RNA was amplified using the primer set published by Kanno et al. [@bib0165]. The 1194 nucleotide section of the S protein gene that was amplified included the polymorphic region of the S protein gene that was used for phylogenetic analysis in previous studies of *Coronavirus* [@bib0135], [@bib0140], [@bib0145], [@bib0150], [@bib0155], [@bib0160], [@bib0165], [@bib0170]. Amplification was confirmed based on size of amplicon as visualized by agarose gel electrophoresis. Amplicons were purified and concentrated using a Geneclean Spin Kit per manufacturers instructions (MP Biomedicals, Solon, Ohio) followed by quantification using the Pico Green assay for ds DNA (Invitrogen Corporation, Carlsbad, CA) and the appropriate quantity of dsDNA was labeled in both directions using Big Dye terminator chemistries (Applied Biosystems Inc., Foster City, CA) according to the manufacturer\'s instructions. The labeled products were sequenced using an ABI 3100 genetic analyzer (Applied Biosystems Inc.). All sequences were confirmed by sequencing both strands and all sequencing reactions were run in duplicate. Sequences were edited and aligned using Sequencher 4.2 (Gene Codes Corporation, Ann Arbor, MI). Final phylogenetic and molecular evolutionary analyses were conducted using Mega version 5.0 (Tamura K, Peterson D, Peterson N, Stecher G, Nei M, and Kumar S (2011) MEGA5: Molecular Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Molecular Biology and Evolution doi:10.1093/molbev/msr121). Analysis was done using Clustal-W based on unpaired geometric mean analysis supported by bootstrapping (5000 replicates). Reference sequences from Genbank used in analysis are listed in [Table 2](#tbl0010){ref-type="table"} . GenBank accession numbers for generated sequences are listed in [Table 3](#tbl0015){ref-type="table"} .Table 2Reference bovine coronavirus strains for sequencing.Ref. strainGenBank Accession NumberClinical presentationRef.182 NS[DQ320764.1](ncbi-n:DQ320764.1)Respiratory diseaseVirus Res 2002;84:101--109232 NS[DQ320763.1](ncbi-n:DQ320763.1)Respiratory diseaseVirus Res 2002;84:101--109DB2[DQ811784.2](ncbi-n:DQ811784.2)Winter dysenteryVirus Res 2002;84:101--109BcoV-LUN[AF391542.1](ncbi-n:AF391542.1)Respiratory diseaseJ Gen Virol 2001;82(Pt 12):2927--2933G95[M80844.1](ncbi-n:M80844.1)Respiratory diseaseArch Virol 1994;134(3--4):421--42643806-TN-50[EU814648.1](ncbi-n:EU814648.1)Respiratory diseaseNew Microbiol 2009;32 (January (1)):109--113BCQ.20UO6092.1Epidemic diarrheaArch Virol 1994;135(3--4):319--331KWD1[AY935637](ncbi-n:AY935637)Winter dysenteryVirus Res 2005;108(1--2):207--212KWD10[AY935646](ncbi-n:AY935646)Winter dysenteryVirus Res 2005;108(1--2):207--212OK-0514-3[AF058944](ncbi-n:AF058944)Respiratory diseaseVirus Genes 1998;17(1):33--42LSU-94LSS-051-2[AF058943](ncbi-n:AF058943)Respiratory diseaseVirus Genes 1998;17(1):33--42F15[D00731](ncbi-n:D00731)EnteritisJ Gen Virol 1990;71(Pt 2):487--492LY138[AF058942](ncbi-n:AF058942)EnteritisVirology 1991;183(1):397--404Nebraska (NVSL)[JQ741969](ncbi-n:JQ741969)EnteritisStrain received from C.A. Mebus and used by NVSL/APHIS as standard reference strainQuebec[AF220295](ncbi-n:AF220295)EnteritisAdv Exp Med Biol 2001;494:73--76CalfGuard-Pfizer[JQ741970](ncbi-n:JQ741970)MLV vaccineMebus[U00735](ncbi-n:U00735)Calf diarrheaAm J Vet Res 1972;33:1147--1156Table 3GenBank Accession Numbers for generated sequences.Sample numberGenBank submission nameAccession \#Isolates with identical sequencesOK AN 3 NSOSU-AN3-00[JQ741947](ncbi-n:JQ741947)OK TN 10 NSOSU-TN10-99[JQ741948](ncbi-n:JQ741948)OK AN 5 NSOSU-AN5-00[JQ741949](ncbi-n:JQ741949)OK 45 NSOSU-43NS-08[JQ741950](ncbi-n:JQ741950)OK 43 NSOK 717 NSOSU-717NS-11[JQ741951](ncbi-n:JQ741951)OK 665 NSOSU-665NS-09[JQ741952](ncbi-n:JQ741952)OK 766 NSOSU-766NS-11[JQ741953](ncbi-n:JQ741953)OK 3171 NSOSU-3171NS-09[JQ741954](ncbi-n:JQ741954)OK 1776 NSOSU-1776NS-09[JQ741955](ncbi-n:JQ741955)OK 778 NSOSU-778NS-09[JQ741956](ncbi-n:JQ741956)OK 778 BALOK 787 NSOSU-787NS-09[JQ741957](ncbi-n:JQ741957)OK 802 NS (53), OK 797 NS, OK 802 NS (42)OK 3175 NSOSU-3175NS-09[JQ741958](ncbi-n:JQ741958)OK 746 BALOSU-746BAL-09[JQ741959](ncbi-n:JQ741959)OK 746 NS, OK 833 NS, OK 747 NSOK 3167 NSOSU-3167NS-09[JQ741960](ncbi-n:JQ741960)OK 747 BALOSU-747BAL-09[JQ741961](ncbi-n:JQ741961)OK 3174 NSOSU-3174NS-09[JQ741962](ncbi-n:JQ741962)OK 3172 NS, OK 3162 NS, OK 3169 NS, OK 3165 NS, OK3163 NS, OK 3181 NS, OK 3168 NS, OK 3170 NS, OK 801 NS, OK 747 BALOK 776 NSOSU-776NS-09[JQ741963](ncbi-n:JQ741963)OK 834 NSOSU-834NS-09[JQ741964](ncbi-n:JQ741964)OK 554 BALOSU-554BAL-09[JQ741965](ncbi-n:JQ741965)OK 538 BALOSU-538BAL-09[JQ741966](ncbi-n:JQ741966)OK 542 BALOSU-542BAL-09[JQ741967](ncbi-n:JQ741967)OK 576 BALOSU-576BAL-09[JQ741968](ncbi-n:JQ741968)OK 592 BAL, OK 603 BAL, OK 600 BAL, OK 545 BAL, OK 575 BAL (15), OK 521 NS, OK 609 BAL, OK 513 BAL, OK 591 BAL, OK 552 BAL, OK 551 BAL (17), OK 1817 NS, OK 603 NS, OK 575 NS, OK 563 BALOK 3166 NSOSU-3166NS-09JX536392Reference strainNebraska (NVSL)\][JQ741969](ncbi-n:JQ741969)Vaccine strainCalfGuard A609860[JQ741970](ncbi-n:JQ741970)

2.6. Determination of serological relatedness {#sec0040}
---------------------------------------------

Endpoint dilutions reflected the highest dilution of serum that inhibited the growth of virus. The serological relatedness was expressed by calculating the ratio (*P*, stated as percentage) of the heterologous VN value as compared to the homologous VN value using the following formula.$$P = 100 \times \frac{\text{BA}}{\text{AA}}$$where BA is the VN titer against strain B using antiserum A and AA is the VN titer against strain A using antiserum A. Statistical significance was evaluated using analysis of variance (ANOVA) and least significant difference (LSD) method. The level of significance was *P*  ≤ 0.05

3. Results {#sec0045}
==========

3.1. Phylogenetic analysis {#sec0050}
--------------------------

In conjunction with the 56 field strains, Spike protein coding sequences were amplified and sequenced from one reference strain received from the National Veterinary Services Laboratory (Nebraska) and one vaccine strain amplified from a vial of modified live vaccine (CalfGuard-Pfizer BCV). Alignment of generated sequences revealed 100% sequence identity between among some strains ([Table 1](#tbl0005){ref-type="table"}). Multiple isolates from the same animal, in all cases, had 100% sequence identity. In addition six clusters of viruses with 100% sequence identity were noted (clusters identified in [Table 1](#tbl0005){ref-type="table"}). The dendogram shown in [Fig. 1](#fig0005){ref-type="fig"} was constructed using sequences of one representative from each of the six clusters (shown in bold lettering) and sequences from the remaining 21 BoCV which did not have 100% sequence identity with any of other BoCV characterized in this study. Phylogenetic analysis, using the 27 sequences generated in this study from field strains of BoCV and sequences from reference strains and a vaccine strain, resulted in a dendogram with two major clades. Clade 1 was composed of reference strains associated with enteric disease and a vaccine strain from a multivalent vaccine for the prevention of scours in calves. Clade 2 was composed of the BoCV field strain panel assembled for this study and reference strains associated with respiratory disease or winter dysentery. Three subgroups (A, B, C in [Fig. 1](#fig0005){ref-type="fig"}) were evident in clade 2. Subgroup A was made up of reference strains from previous studies and three isolates from the BoCV field strain panel. The other two subgroups were made up entirely of isolates from the BoCV field strain panel.Fig. 1Dendogram of representative BoCV of the six clusters and the reference strains.

In the study described, there were instances where there were BoCV that were identical ([Table 1](#tbl0005){ref-type="table"}, [Table 3](#tbl0015){ref-type="table"}). There were identical viruses from different studies over time. However there were instances where there were calves with nonidentical BoCV in the same subclade such as in OSU-2. Also in OSU-2 there were mixtures of multiple BoCV subclades including BoCV2b and BoCV2c. Because these calves in the OSU studies 1--5 were cattle purchased at auction markets, these isolates likely reflect exposure to multiple sources of viruses.

3.2. Determination of serological relatedness {#sec0055}
---------------------------------------------

Convalescent sera collected from animals exposed to BoCV strains from clade 2, subgroup A, could not be used to differentiate viruses from clades 1 and 2. ([Fig. 2](#fig0010){ref-type="fig"} ) The error bars in [Fig. 2](#fig0010){ref-type="fig"} represent standard error of the mean. In contrast, convalescent sera collected from animals exposed to BoCV strains from clade 2, subgroups B and C, did have a statistically significant (*P*  \< 0.05) greater neutralizing power for strains from clade 2 as opposed to one strain from clade 1. There was no statistically significant difference between neutralization of any of the clade 2 subgroups using any of the sera evaluated.Fig. 2Convalescent serology with each subclade strains against serums from calves with respective subclade virus.

4. Discussion {#sec0060}
=============

BoCV were initially identified as enteric pathogens and vaccines are available for control of BoCV in calves. However, more recently, BoCV has been isolated in conjunction with BRD in feeder and stockyard cattle. This raises several questions. Is there is a difference between BoCV associated with enteric disease and BoCV associated with respiratory disease? Are BoCV evolving over time so that recent isolates are detectably different from reference strains isolated 50--60 years ago? Are differences between recently isolated strains and vaccine strains of practical significance?

Previously, the S protein coding sequences were compared from nine BoCV isolates that were isolated from dysentery cases in Korean cattle between 2002 and 2003 were compared to previously characterized BoCV strains [@bib0175]. These nine isolates were more closely related to the more recently isolated respiratory BCoV strain OK and the enteric BCoV strain LY-138 than to the prototype BoCV reference strain Mebus. They hypothesized that BoCV were evolving over time and may be diverging from an enteric tropism to a dual respiratory and enteric tropism. Similarly, Kanno et al. compared the S protein coding sequences from 55 BoCV collected in Japan from 1999 to 2000 to reference strains [@bib0165]. They concluded that these 55 isolates had distinctive genetic divergence from the prototype enteric BoCV strains (Mebus, Quebec, Kakegawa, F15 and LY138). The study reported herein expands on these observations. In addition to comparing S protein coding sequences of recent U.S. isolates to reference strains, we have also compared these strains to a vaccine strain and have conducted an antigenic comparison using convalescent sera from cattle exposed to BoCV. Our results suggest that BoCV strains currently circulating in the U.S., similar to recent Japanese and Korean strains, are divergent from prototype BoCV strains isolated, in some cases 50 to 60 years ago. Further, there are antigenic differences between these more recent strains and a prototype strain Mebus. These results are consistent with a divergence of BoCV over time. Whether this divergence is associated with an increased tropism for respiratory tissue resulting in an increased association with respiratory disease is a matter for future study. Differences in cell tropism, that result in different clinical presentations, have been observed with other coronaviruess. Transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV) are both pathogens of swine that co-circulate in swine herds [@bib0180], [@bib0185]. TGEV replicates primarily in the enteric tract and PRCV replicates almost exclusively in the respiratory tract. In the case of porcine coronaviruses, changes in cell tropism are associated with variations of the S gene. It appears that PRCV may be a deletion mutant of TGEV [@bib0190]. In comparison to TGEV, PRCV has a large deletion in the 5′ region of the S gene and minor deletions in genes 3/2a and 3--1/3b [@bib0195]. It is theorized, based on studies using TGEV mutants, that mutations located in the S gene affect tissue tropism and virulence [@bib0200], [@bib0205].

Differences, observed in this study, between the strain used in a vaccine for the control of BoCV associated enteric disease, and more recently isolated BoCV suggest that the vaccine may not be fully protective against BoCV isolates currently in circulation. Further research is needed to determine if BoCV are diverging from an enteric tropism to a dual respiratory and enteric tropism and if control of BoCV will reduce BRD losses.

In this study diversity of the BoCV subclades in the cattle was observed in calves that were sampled at arrival. These cattle were most likely purchased from multiple herds at the auction markets. This diversity points out the need to determine if potential immunizations provide broad range of protection to these heterologous BoCV. Another point is that these cattle in the OSU1-5 studies were found to be shedding viruses at arrival or short after arrival [@bib0095]. Thus immunizations for control of BoCV should be performed prior to the cattle being exposed to the virus in the marketing and shipping channels. BoCV control programs using vaccination would appear best done at the originating breeding herd.

If BoCV has become a respiratory pathogen, differences between the strain used in vaccines for enteric disease may not provide the protection expected of immunization. Studies should be performed to determine if the current vaccine (BoCV clade 1) provides adequate protection against the BoCV subclades 2a,2b,or 2c. Or potentially the BoCV clade 2 strains might be developed as immunogens including subclades 2a,2b and 2c as well. Ideally vaccine efficacy would utilize animal challenge with clinical signs and lesions due to virulent challenge demonstrating protection. Another approach with approval might utilize reduction of viral shedding as a measure of vaccine efficacy. Also surveillance programs should be maintained to determine if additional BoCV clades are present in the cattle populations.

5. Conclusions {#sec0065}
==============

This study was the initial study in the U.S. to examine genetic differences among BoCV isolated from the respiratory tract in cattle from various Oklahoma studies. There were two clades identified (BoCV 1 and 2), and there were three subclades for the BoCV2 clade (a,b, and c). There were antigenic differences detected based on virus neutralization tests using multiple strains from each subclade. Our results indicate genetic and antigenic differences, and thus these results have potential application for immunogens. The MLV vaccine available in the U.S. is a member of the BoCV clade 1, and our respiratory isolates were in BoCV clade 2. The current MLV vaccine should be tested for protection against the BoCV clade 2 viruses, or the BoCV clade 2 viruses might be incorporated into the existing BoCV clade 1 vaccine.
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[^1]: \(1\) identical; (2) identical; (3) identical; (4) identical; (5) identical; (6) identical.
